NIH-funded research R03 grant

Exploring how diet and exercise affect survival in kidney cancer patients

Official title: Informing Lifestyle Recommendations for Kidney Cancer Survival: Investigating the Role of Dietary Patterns and Physical (In)activity

Funded at Brigham and Women's Hospital · NIH-10950992 · Data updated 2026-11-12

This study is looking at how healthy eating and staying active can help people with kidney cancer live longer and feel better, so they can make smart choices about their lifestyle during treatment.

More Kidney Cancer research and trials

Quick facts

Grant typeR03 grant
Study typeNIH-funded research
Funding institutionBrigham and Women's Hospital
NIH-funded
Lab location1 site (Boston, United States)
Project startSeptember 20, 2024
Project endAugust 31, 2026
Funding year2024
Award (this year)$189,163
NIH project number1R03CA282955-01A1
Project IDNIH-10950992 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with renal cell carcinoma who are seeking ways to enhance their chances of survival through lifestyle modifications.

Less likely to help

Patients with advanced-stage kidney cancer or those who are not interested in making lifestyle changes may not benefit from this research.

What this research studies

This research investigates the impact of dietary patterns and physical activity on the survival of patients diagnosed with renal cell carcinoma (RCC). By analyzing data from large cohorts, the study aims to identify specific lifestyle changes that could enhance survival rates. Patients will be assessed on their adherence to healthy eating patterns and levels of physical activity before and after their diagnosis. The goal is to provide evidence-based recommendations that can empower patients to make informed lifestyle choices during their cancer journey.

Why it matters

Potential benefit: If successful, this research could lead to tailored lifestyle recommendations that improve survival rates for kidney cancer patients.

How similar studies have gone: Previous research has shown promising results in similar studies that link lifestyle changes to improved cancer outcomes, suggesting this approach could be beneficial.

Where this research is happening

  • Brigham and Women's Hospital
    Boston, United States
    Active

Researchers

  • Principal investigator: Preston, Mark Arthur — Brigham and Women's Hospital
  • Study coordinator: Preston, Mark Arthur

Related research

Other NIH-funded projects on the same topics.

  • Maximizing anti-tumor immune responses in kidney cancer

    A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.

    NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11561063

  • Kidney Cancer Career Enhancement Program (CEP) at DF/HCC

    A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.

    NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11421802

  • Kidney Cancer Development Program at DF/HCC

    A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.

    NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11421801

  • Personalized antigens for kidney cancer therapy

    This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.

    NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11421800

  • Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer

    A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.

    NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11421799

  • Targeting the HIF2 Pathway in Kidney Cancer

    A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.

    NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11421798

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.